Columbus, Ohio
Founders and CEO
Michael Triplett, Ph.D., CEO
Louise Rodino-Klapac, Ph.D.
Life Sciences

Company Profile

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital, a leader in neuromuscular disease gene therapy discovery and clinical translation.

Blogs About Myonexus Therapeutics

Video: Serial Entrepreneur Tells Compelling Personal Story about His Entrepreneurial Path
Serial Entrepreneur
Myonexus Poised to Unlock Gene Therapy for Limb-Girdle Muscular Dystrophy

Myonexus Therapeutics in the News

Limb Girdle Muscular Dystrophy (LGMD) Market Potential Growth, Share, Demand and Analysis of Key Players & Forecasts to 2030
Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition
Sarepta Acquires Gene-Therapy Startup Myonexus Therapeutics for $165 Million
The Wall Street Journal
Nationwide Children’s gene therapy inventors hired away by pharma giants – why that’s good for recruitment
Columbus Business First
Gene Therapy Ever More Common for Rare Disorders
generic engineering & biotechnology